Iron Chelation as Novel Treatment for Interstitial Cystitis.

Abstract

Interstitial cystitis (IC) is a highly prevalent debilitating disease, with its cardinal symptoms being severe pain, urinary urgency and frequency. The associated pain may eventually lead as a last resort to removal of the bladder. Though the initial trigger for IC remains largely unknown, we propose novel iron chelators as a possible new treatment for this disease. Iron is a mandatory component for the generation of reactive oxygen species (ROS). A substantial decrease in ROS production and thus inflammation can be achieved by effectively sequestering host iron, which we believe may improve outcome and quality of life in IC patients. Novel iron chelators could be used via the intravesical route to reduce or attenuate inflammation by effectively sequestering host iron, thus preventing the production of ROS via the Fenton and Haber-Weiss reactions.

• Authors: Georg Hagn, Robert Westhofen, Ian Burkovskiy, Bruce Holbein, Juan Zhou, Christian Lehmann
• Journal: Pharmacology (Pharmacology) Vol. 103 Issue 3-4 Pg. 159-162 ( 2019) ISSN: 1423-0313 [Electronic] Switzerland
• PMID: 30695781 (Publication Type: Journal Article)
• Copyright: © 2019 S. Karger AG, Basel.

Chemical References

• Anti-Inflammatory Agents
• Antioxidants
• Inflammation Mediators
• Iron Chelating Agents
• Reactive Oxygen Species

Topics

• Administration, Intravesical
• Animals
• Anti-Inflammatory Agents (administration & dosage)
• Antioxidants (administration & dosage)
• Cystitis, Interstitial (drug therapy, metabolism, physiopathology)
• Humans
• Inflammation Mediators (metabolism)
• Iron Chelating Agents (administration & dosage)
• Oxidative Stress (drug effects)
• Reactive Oxygen Species (metabolism)
• Urinary Bladder (drug effects, metabolism, physiopathology)